葡萄糖胺诱导的脱细胞体在帕金森病中传播致病性α-synuclein
Julie Jacquemyn1,2,3,4, Brian Marriott1,4, Jinlan Chang1
1Department of Physiology, University of Alberta, Edmonton, Alberta, Canada.
Nature cell biology
|February 12, 2026
概括
帕金森病涉及阿尔法同核素的传播. 改变的脂质,特别是由于β-葡萄糖核糖酶活性降低而增加的葡萄糖胺,促进了ectosome释放,这是α-synuclein传播的关键途径.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 遗传学 是一个遗传学.
背景情况:
- 细胞间传输的α-synuclein (α-synuclein) 是帕金森病 (PD) 病理学的关键因素.
- 驱动神经元之间的α-synuclein传播的精确机制仍然不完全理解.
- 脂质变化越来越多地与神经退行性疾病有关,但它们在α-synuclein释放中的作用尚不清楚.
研究的目的:
- 研究帕金森病相关的脂质变化如何影响神经元中α-synuclein的释放.
- 确定负责α-synuclein细胞间传播的特定细胞机制.
主要方法:
- 使用活细胞显微镜观察α-synuclein释放动态.
- 使用初级神经元和患者衍生的多巴胺基神经元 (携带GBA1和LRRK2突变).
- 葡萄糖胺水平和β-葡萄糖脑酶酶抑制对囊泡释放的影响在试验室和小鼠大脑中进行了评估.
主要成果:
- 增加的葡萄糖胺,由于β-葡萄糖脑糖酶活性降低,显著增强了来自神经元的ectosome脱落.
- 这种效应在患有特定GBA1和LRRK2突变的PD患者的初级神经元和患者衍生的多巴氨基神经元中观察到.
- 在小鼠大脑模型中,高水平的葡萄糖胺和药理上抑制β-葡萄糖脑酶酶促进了囊泡的释放,并随后被其他神经元吸收.
- 检测结果显示,ectosomes中含有α-synuclein,这有助于病态扩散到邻近的神经元.
结论:
- 在帕金森病中,赤色体代表了α-synuclein细胞间传播的重要机制.
- 改变的脂质代谢,特别是高水平的葡萄糖胺,驱动着ectosome介导的α-synuclein传播.
- 准脂质变化和外皮细胞形成可能为帕金森病提供新的治疗策略.
相关概念视频
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
01:22Lysosomal Hydrolases
3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28